Log in
Enquire now
Calimmune

Calimmune

Calimmune is a biotechnology company developing gene and stem cell therapies for treating rare and serious diseases.

OverviewStructured DataIssuesContributors
Is a
Company
Company
Organization
Organization
B2X
B2B
B2B
CEO
‌
Louis Breton
CIK Number
1,643,405
Legal Name
Calimmune, Inc.
Company Operating Status
Closed
Country
United States
United States
Crunchbase URL
crunchbase.com/organiz...alimmune
Date Incorporated
2006
Founded Date
January 1, 2006
Founder
David Baltimore
David Baltimore
‌
Louis Breton
Full Address
5151 East Broadway Boulevard Suite 1020 Tucson, AZ 85711 United States
Glassdoor ID
990372
Industry
Regenerative medicine
Regenerative medicine
Stem cell
Stem cell
Gene therapy
Gene therapy
Healthcare
Healthcare
Genetics
Genetics
Therapeutics
Therapeutics
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Genetic engineering
Genetic engineering
Investors
‌
Translational Accelerator
RA Capital Management
RA Capital Management
Alexandria Venture Investments
Alexandria Venture Investments
Mark Solon
Mark Solon
Latest Funding Round Date
May 2015
Latest Funding Type
Series B
Series B
Legal classification
Corporation
Corporation
LinkedIn URL
@company/calimmune-inc/about
Location
United States
United States
Los Angeles
Los Angeles
California
California
Tucson, Arizona
Tucson, Arizona
King of Prussia, Pennsylvania
King of Prussia, Pennsylvania
Number of Employees (Ranges)
1 – 10
Patents Assigned (Count)
1
Total Funding Amount (USD)
15,900,000
Twitter URL
@cslbehring
Official Website
calimmune.com
Wikidata ID
Q36875407

Find more companies like Calimmune

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.